Published in J Gastroenterol Hepatol on January 01, 2012
Which Therapy for Helicobacter pylori Infection? Gastroenterology (2012) 1.10
Treatment of Helicobacter pylori infection: Current and future insights. World J Clin Cases (2016) 0.92
The effects of varying acidity on Helicobacter pylori growth and the bactericidal efficacy of ampicillin. Aliment Pharmacol Ther (2012) 0.92
Helicobacter pylori Eradication Therapy: Current Availabilities. ISRN Gastroenterol (2012) 0.91
High-dose extended-release lansoprazole (dexlansoprazole) and amoxicillin dual therapy for Helicobacter pylori infections. Helicobacter (2014) 0.91
Seeking an optimal eradication therapy for Helicobacter pylori infection. J Gastroenterol Hepatol (2012) 0.76
Failure of optimized dual proton pump inhibitor amoxicillin therapy: What now? Saudi J Gastroenterol (2017) 0.75
Persister cells, dormancy and infectious disease. Nat Rev Microbiol (2006) 8.35
Persister cells and tolerance to antimicrobials. FEMS Microbiol Lett (2004) 5.23
Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut (2010) 4.43
New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol (2008) 2.83
The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology (1999) 2.64
Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. Gut (2006) 2.56
A report card to grade Helicobacter pylori therapy. Helicobacter (2007) 2.41
Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter (1996) 2.26
Why is long-term therapy required to cure tuberculosis? PLoS Med (2007) 2.03
Efficient identification and evaluation of effective Helicobacter pylori therapies. Clin Gastroenterol Hepatol (2008) 1.52
A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther (2000) 1.36
Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis. Int J Epidemiol (2002) 1.34
Pharmacologic aspects of eradication therapy for Helicobacter pylori Infection. Gastroenterol Clin North Am (2010) 1.26
Does Helicobacter pylori eradication depend on the period of amoxicillin treatment? A retrospective study. J Gastroenterol (1998) 0.94
Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut (2012) 12.62
Traces of human migrations in Helicobacter pylori populations. Science (2003) 11.92
Norwalk virus infection and disease is associated with ABO histo-blood group type. J Infect Dis (2002) 5.09
Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med (2011) 3.78
Norwalk virus shedding after experimental human infection. Emerg Infect Dis (2008) 3.70
Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am J Gastroenterol (2005) 3.34
Importance of Helicobacter pylori oipA in clinical presentation, gastric inflammation, and mucosal interleukin 8 production. Gastroenterology (2002) 3.27
The peopling of the Pacific from a bacterial perspective. Science (2009) 3.14
Proton pump inhibitor use and recurrent Clostridium difficile-associated disease: a case-control analysis matched by propensity score. J Clin Gastroenterol (2012) 2.99
Gastroesophageal reflux among different racial groups in the United States. Gastroenterology (2004) 2.87
Age at acquisition of Helicobacter pylori infection: a follow-up study from infancy to adulthood. Lancet (2002) 2.71
Helicobacter pylori in North and South America before Columbus. FEBS Lett (2002) 2.57
Determination of the 50% human infectious dose for Norwalk virus. J Infect Dis (2013) 2.50
A report card to grade Helicobacter pylori therapy. Helicobacter (2007) 2.41
Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1beta production in Helicobacter pylori infection. Gastroenterology (2002) 2.32
Serological correlate of protection against norovirus-induced gastroenteritis. J Infect Dis (2010) 2.21
Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol (2009) 2.15
Comparing the Blatchford and pre-endoscopic Rockall score in predicting the need for endoscopic therapy in patients with upper GI hemorrhage. Gastrointest Endosc (2010) 2.04
Duodenal ulcer promoting gene of Helicobacter pylori. Gastroenterology (2005) 2.03
Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter (2009) 2.02
Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol (2011) 1.98
Gastritis staging in clinical practice: the OLGA staging system. Gut (2006) 1.90
Risk factors for immediate and delayed bleeding associated with endoscopic submucosal dissection of gastric neoplastic lesions. Scand J Gastroenterol (2009) 1.75
NSAIDs, Helicobacter pylori, and Pandora's Box. N Engl J Med (2002) 1.75
Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter (2011) 1.73
Discrimination between cases of duodenal ulcer and gastritis on the basis of putative virulence factors of Helicobacter pylori. J Clin Microbiol (2002) 1.72
Patterns of gastric atrophy in intestinal type gastric carcinoma. Cancer (2002) 1.69
Biliary stenting in the management of large or multiple common bile duct stones. Gastrointest Endosc (2010) 1.68
Management of gastric polyps: a pathology-based guide for gastroenterologists. Nat Rev Gastroenterol Hepatol (2009) 1.62
Role of interferon-stimulated responsive element-like element in interleukin-8 promoter in Helicobacter pylori infection. Gastroenterology (2004) 1.59
Helicobacter pylori infection in mice: Role of outer membrane proteins in colonization and inflammation. Gastroenterology (2002) 1.58
Iron deficiency and Helicobacter pylori infection in the United States. Am J Epidemiol (2005) 1.57
Endoscopic demonstration of transient small bowel intussusception in a patient with adult celiac disease. Gastrointest Endosc (2003) 1.55
Helicobacter pylori-negative gastritis: prevalence and risk factors. Am J Gastroenterol (2012) 1.51
Horizontal versus familial transmission of Helicobacter pylori. PLoS Pathog (2008) 1.48
Helicobacter pylori eradication and change in markers of iron stores among non-iron-deficient children in El Paso, Texas: an etiologic intervention study. J Pediatr Gastroenterol Nutr (2011) 1.47
Helicobacter pylori virulence factors: facts and fantasies. Curr Opin Gastroenterol (2005) 1.44
Etest for metronidazole susceptibility in H. pylori: use of the wrong standard may have led to the wrong conclusion. Am J Gastroenterol (2004) 1.43
Effect of the carbonic anhydrase inhibitor, acetazolamide, on Helicobacter pylori infection in vivo: a pilot study. Helicobacter (2005) 1.42
Waist-to-hip ratio, but not body mass index, is associated with an increased risk of Barrett's esophagus in white men. Clin Gastroenterol Hepatol (2012) 1.41
Expression of B7-H1 on gastric epithelial cells: its potential role in regulating T cells during Helicobacter pylori infection. J Immunol (2006) 1.41
Double-blind randomized trial of quadruple sequential Helicobacter pylori eradication therapy in asymptomatic infected children in El Paso, Texas. J Pediatr Gastroenterol Nutr (2011) 1.40
Helicobacter pylori infection--a boon or a bane: lessons from studies in a low-prevalence population. Helicobacter (2013) 1.38
Regulation of interleukin-6 promoter activation in gastric epithelial cells infected with Helicobacter pylori. Mol Biol Cell (2005) 1.37
Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med (2002) 1.35
Molecular epidemiology and outcome of Helicobacter pylori infection in Thailand: a cultural cross roads. Helicobacter (2004) 1.35
Clinical presentation in relation to diversity within the Helicobacter pylori cag pathogenicity island. Am J Gastroenterol (2002) 1.34
Diagnosis and management of iron deficiency anemia in the 21st century. Therap Adv Gastroenterol (2011) 1.30
Helicobacter pylori infection in Kazakhstan: effect of water source and household hygiene. Am J Trop Med Hyg (2002) 1.29
Eradication of gastric cancer is now both possible and practical. Semin Cancer Biol (2013) 1.28
Correlation between Helicobacter pylori OipA protein expression and oipA gene switch status. J Clin Microbiol (2004) 1.27
Pharmacologic aspects of eradication therapy for Helicobacter pylori Infection. Gastroenterol Clin North Am (2010) 1.26
Helicobacter pylori and hetertopic gastric mucosa in the upper esophagus (the inlet patch). Am J Gastroenterol (2003) 1.25
Importance of atrophic gastritis in diagnostics and prevention of gastric cancer: application of plasma biomarkers. Scand J Gastroenterol (2007) 1.22
Helicobacter pylori virulence and cancer pathogenesis. Future Oncol (2014) 1.21
Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14 days? Helicobacter (2011) 1.21
Serological responses to experimental Norwalk virus infection measured using a quantitative duplex time-resolved fluorescence immunoassay. Clin Vaccine Immunol (2011) 1.20
Helicobacter pylori activate epidermal growth factor receptor- and phosphatidylinositol 3-OH kinase-dependent Akt and glycogen synthase kinase 3beta phosphorylation. Cell Microbiol (2008) 1.19
Helicobacter pylori impairs DNA mismatch repair in gastric epithelial cells. Gastroenterology (2002) 1.19
vacA i-region subtyping. Gastroenterology (2008) 1.18
Diet, lifestyle and gender in gastro-esophageal reflux disease. Dig Dis Sci (2007) 1.16
Management of gastric polyps: an endoscopy-based approach. Clin Gastroenterol Hepatol (2013) 1.15
Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett's oesophagus: a case-control study. Gut (2013) 1.14
Role of deletion located between the intermediate and middle regions of the Helicobacter pylori vacA gene in cases of gastroduodenal diseases. J Clin Microbiol (2009) 1.13
Comparison of genotyping Helicobacter pylori directly from biopsy specimens and genotyping from bacterial cultures. J Clin Microbiol (2003) 1.13
Regulation of RANTES promoter activation in gastric epithelial cells infected with Helicobacter pylori. Infect Immun (2005) 1.12
Cross-reactivity of anti-CagA antibodies with vascular wall antigens: possible pathogenic link between Helicobacter pylori infection and atherosclerosis. Circulation (2002) 1.11
Molecular markers in Helicobacter pylori-associated gastric carcinogenesis. Clin Lab Med (2005) 1.11
The Role of CD44 in the Pathogenesis, Diagnosis, and Therapy of Gastric Cancer. Gut Liver (2011) 1.11
Serum hemagglutination inhibition activity correlates with protection from gastroenteritis in persons infected with Norwalk virus. Clin Vaccine Immunol (2011) 1.10
Which Therapy for Helicobacter pylori Infection? Gastroenterology (2012) 1.10
Genetic analysis of Helicobacter pylori strain populations colonizing the stomach at different times postinfection. J Bacteriol (2007) 1.09
Helicobacter pylori research: historical insights and future directions. Nat Rev Gastroenterol Hepatol (2013) 1.09
Gastric mucosal interleukin-17 and -18 mRNA expression in Helicobacter pylori-induced Mongolian gerbils. Cancer Sci (2009) 1.09
Strategy for eliminating gastric cancer in Japan. Helicobacter (2010) 1.08
Helicobacter pylori BabA expression, gastric mucosal injury, and clinical outcome. Clin Gastroenterol Hepatol (2006) 1.08
Randomized, double-blind, pilot study of geranylgeranylacetone versus placebo in patients taking low-dose enteric-coated aspirin. Low-dose aspirin-induced small bowel damage. Scand J Gastroenterol (2010) 1.07
Sociocultural and dietary practices among Malay subjects in the north-eastern region of Peninsular Malaysia: a region of low prevalence of Helicobacter pylori infection. Helicobacter (2012) 1.06
Functional and intracellular signaling differences associated with the Helicobacter pylori AlpAB adhesin from Western and East Asian strains. J Biol Chem (2007) 1.06
The intact dupA cluster is a more reliable Helicobacter pylori virulence marker than dupA alone. Infect Immun (2011) 1.06
OipA plays a role in Helicobacter pylori-induced focal adhesion kinase activation and cytoskeletal re-organization. Cell Microbiol (2007) 1.03
Polyomavirus shedding in the stool of healthy adults. J Clin Microbiol (2009) 1.03
Operative link for gastritis assessment vs operative link on intestinal metaplasia assessment. World J Gastroenterol (2011) 1.03
Histological risk markers for non-cardia early gastric cancer. Pattern of mucin expression and gastric cancer. Virchows Arch (2006) 1.03
Prevention of gastric cancer by Helicobacter pylori eradication. Intern Med (2010) 1.03
Evidence-based examination of the African enigma in relation to Helicobacter pylori infection. Scand J Gastroenterol (2005) 1.03
Evidence-based recommendations for successful Helicobacter pylori treatment. Expert Rev Gastroenterol Hepatol (2013) 1.02
Dramatic changes in the prevalence of Helicobacter pylori infection during childhood: a 10-year follow-up study in Russia. J Pediatr Gastroenterol Nutr (2007) 1.02
CpG methylation and reduced expression of O6-methylguanine DNA methyltransferase is associated with Helicobacter pylori infection. Gastroenterology (2010) 1.02
Unreliability of results of PCR detection of Helicobacter pylori in clinical or environmental samples. J Clin Microbiol (2009) 1.02
Circulating tumor cells in the diagnosis and management of pancreatic cancer. Biochim Biophys Acta (2012) 1.02
Helicobacter pylori therapy demystified. Helicobacter (2011) 1.01
Visualization of the small intestine using capsule endoscopy in healthy subjects. Dig Dis Sci (2007) 1.01
Balance between polyoma enhancing activator 3 and activator protein 1 regulates Helicobacter pylori-stimulated matrix metalloproteinase 1 expression. Cancer Res (2006) 1.01
Helicobacter infection in patients with HCV-related chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Dig Dis Sci (2002) 1.00
New serological assay for detection of putative Helicobacter pylori virulence factors. J Clin Microbiol (2002) 0.99
Furazolidone in Helicobacter pylori therapy: misunderstood and often unfairly maligned drug told in a story of French bread. Saudi J Gastroenterol (2012) 0.99
Effects of blood group antigen-binding adhesin expression during Helicobacter pylori infection of Mongolian gerbils. J Infect Dis (2011) 0.99
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days. Helicobacter (2011) 0.99